The drug-pricing watchdogs over at the Institute for Clinical and Economic Review tend to be supportive of gene therapy ...
Swiss drugmaker Sandoz launched its biosimilar Hyrimoz with the same prices as Boehringer and Amgen, whose Amjevita was the first Humira biosimilar to hit the U.S. market, priced at a 5% and 55% ...
In recent years, Amgen has been using acquisitions as a way to bolster its competitive position. And that's the big unknown for investors going forward: whether its recent purchases will pay off.
The Westchester-based unit of New Jersey-based Kenvue is closing its corporate headquarters at 6080 West Center Drive to ...
As with Epogen, the initial discoveries that laid the basis for the drug had ... That decade of investment and research was paying off. In 1992, Amgen hit the billion dollars sales mark and ...
Chroma Medicine laid off an undisclosed number of employees ... Sandoz reached an agreement with Amgen to resolve all patent litigation. Merck reported positive results from a trial for its pneumonia ...
April 4 (Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its salesforce due ... with the same prices as Boehringer and Amgen, whose Amjevita was the first Humira ...
(Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its U.S. salesforce due to poor sales ... its biosimilar Hyrimoz with the same prices as Boehringer and Amgen, whose Amjevita ...